Intellia Therapeutics Inc

NTLA

$136.57

+646.7% (1 year change)

Market Cap

$9.34 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$16.54 - $202.73

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

-62.83x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $9.34 Billion
Enterprise Value $8.75 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return +646.7%
52-Week High $202.73
52-Week Low $16.54
Beta 2.2
Outstanding Shares 68.2 Million
Avg 30 Day Volume 1.91 Million

Valuation

P/E Ratio -62.83
PEG -138.79
Earnings per Share -$2.47
Price to Sales Ratio Infinity
Price to Book Ratio 17.07
Revenue to Enterprise Value 169.91
EBIT to Enterprise Value -58.38
Total Debt to Enterprise Value 0.0
Debt to Equity 0.0

Profitability

Revenue $51.5 Million
Gross Profit $51.5 Million
EBIT -$150 Million
Net Income -$149 Million
Profit Margin -288.47%
Quarterly Earnings Growth (YoY) +45.3%
Return on Equity -27.23%
Return on Assets -20.73%
Return on Invested Capital -22.85%

Intellia Therapeutics Inc

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Therapeutics was founded in May 2014 to develop biopharmaceuticals using CRISPR.

News

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates

CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRIS...

Intrado Digital Media Intrado Digital Media, 5 days ago
Intellia Therapeutics'' Next Hurdles After Its Positive Clinical Results

Intellia Therapeutics'' Next Hurdles After Its Positive Clinical Results

There are still some key unanswered questions for the biotech''s promising gene-editing therapy.

The Motley Fool The Motley Fool, 23 days ago
Seeking to Play Intellias Floor-Breaking Gene Remedy?

Seeking to Play Intellias Floor-Breaking Gene Remedy?

Intellia Therapeutics (NTLA) CEO John Leonard believes that gene-editing remedy may come to market very, very quickly, in response to an interview on CNBCs Closing Bell, after information broke tha...

FXNews24 FXNews24, 28 days ago